PHARMACOECONOMIC STUDY OF THE INTERRUPTION OF TREATMENT WITH TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA. EXPERIENCE IN REAL CLINICAL PRACTICE

被引：0
|
作者：
Merchan, Munoz B. [1 ]
Nuevo, Lopez, I [1 ]
De Miguel, Llorente D. [1 ]
Gil, Perez A. [1 ]
Morales, Sanz M. D. [1 ]
Perez, Ortega A. [1 ]
Guillen, Garcia H. [1 ]
Mora, Argumanez M. [1 ]
Vazquez, Ramo A. [1 ]
Santos, Morales A. B. [1 ]
Golbano, Lopez N. [1 ]
Herrero, Martin S. [1 ]
Arbeteta, Juanis J. [1 ]
Subira, D. [1 ]
机构：
[1] Hosp Univ Guadalajara, Dept Hematol, Guadalajara, Spain
来源：
HAEMATOLOGICA | 2020年 / 105卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO-029
引用
收藏
页码：153 / 154
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics of Four Tyrosine Kinase Inhibitors in Adult and Paediatric Chronic Myeloid Leukaemia Patients
    Allegra, Sarah
    Dondi, Emma
    Chiara, Francesco
    De Francia, Silvia
    BIOMEDICINES, 2023, 11 (09)
  • [22] Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors
    Casavecchia, Grazia
    Spinosa, Giuseppina
    De Gennaro, Luisa
    Zicchino, Stefano
    Gravina, Matteo
    Magnesa, Michele
    Di Biase, Matteo
    Brunetti, Natale Daniele
    ACTA CARDIOLOGICA, 2022, 77 (02) : 130 - 135
  • [23] Chakalaka-induced vasodilatation in patients with chronic myeloid leukaemia on tyrosine kinase inhibitors
    Coetzee, Marius J.
    Louw, Vernon J.
    Gartrell, Kevin
    Viljoen, Chris D.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2009, 99 (12): : 870 - 871
  • [24] A REAL-WORLD PRACTICE OF TYROSINE KINASE INHIBITOR CESSATION IN CHRONIC MYELOID LEUKAEMIA IN MALAYSIA
    Chong, Siew Lian
    Wong, Tien Gen
    Sharif, Azizan
    Boo, Yang Liang
    Liam, Christopher
    Teoh, Ching Soon
    Ho, Kim Wah
    Tan, Jenq Tzong
    Asnawi, Asral Wirda Ahmad
    Ong, Tee Chuan
    Lim, Soo Min
    Goh, Ai Sim
    Tan, Sen Mui
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 43 - 43
  • [25] Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
    Gianantonio Rosti
    Fausto Castagnetti
    Gabriele Gugliotta
    Michele Baccarani
    Nature Reviews Clinical Oncology, 2017, 14 : 141 - 154
  • [26] Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease
    Leong, Darryl
    Aghel, Nazanin
    Hillis, Christopher
    Siegal, Deborah
    Karampatos, Sarah
    Rangarajan, Sumathy
    Pond, Gregory
    Seow, Hsien
    HEART, 2021, 107 (08) : 667 - 673
  • [27] Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
    Rosti, Gianantonio
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Baccarani, Michele
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (03) : 141 - 154
  • [28] Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia
    Goldman, JM
    LANCET, 2000, 355 (9209): : 1031 - 1032
  • [29] Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
    Tolomeo, Manlio
    Dieli, Francesco
    Gebbia, Nicola
    Simoni, Daniele
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2009, 9 (08) : 853 - 863
  • [30] Cutaneous adverse reactions to tyrosine kinase inhibitors in a cohort of patients treated for chronic myeloid leukaemia
    Sears, A.
    Orrin, E.
    Salisbury, J.
    Mufti, G.
    De Lavallade, H.
    Basu, T.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 : 52 - 52
12345